

Supporting Information for

1,3-Iodo-Amination of 2-Methyl Indoles as C_{sp2}–C_{sp3} Dual Functionalization with Iodine Reagent

Katsuhiko Moriyama,^{*†‡} Tsukasa Hamada,[†] Kazuma Ishida,[†] and Hideo Togo[†]

Department of Chemistry, Graduate School of Science, Chiba University,[†]

Yayoi-cho 1-33, Inage-ku, Chiba, 263-8522, Japan

Molecular Chirality Research Center, Chiba University,[‡]

1-33 Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan

moriyama@faculty.chiba-u.jp


Table of contents

1. General Methods.	-----	S2
2. Procedure for Preparation of Indolyl(phenyl)iodonium Imides (2a) (Scheme 1; eq. 3).	-----	S2
3. Procedure for Iodo-amination of Indolyl(phenyl)iodonium Imides (2a) (Scheme 1; eq. 4).	-----	S4
4. General Procedure for Direct Iodo-amination of 2-Methyl Indole Derivatives (1) with PhI(OAc) ₂ and DIH (Method A) (Scheme 2; eq. 5, Table 1, and Table 2).	-----	S6
5. General Procedure for Direct Iodo-amination of 2-Methyl Indole Derivatives (1) with DIH (Method B) (Scheme 2; eq. 6, Table 1, and Table 2).	-----	S6
6. Derivatization of 2-Aminomethyl-3-iodo indole Derivatives (3b) (Scheme 5).	-----	S15
7. ¹ H and ¹³ C NMR Spectra of Materials	-----	S23

1. General Methods. ^1H NMR spectra were measured on a JEOL ECS-400 (400 MHz) spectrometer at ambient temperature. Data were recorded as follows: chemical shift in ppm from internal tetramethylsilane on the δ scale, multiplicity (s = singlet; d = doublet; t = triplet; q = quartet; sep = septet; m = multiplet; br = broad), coupling constant (Hz), integration, and assignment. ^{13}C NMR spectra were measured on a JEOL ECS-400 (100 MHz) spectrometer. Chemical shifts were recorded in ppm from the solvent resonance employed as the internal standard (deuteriochloroform at 77.0 ppm). High-resolution mass spectra were recorded by Thermo Fisher Scientific Exactive Orbitrap mass spectrometers. Infrared (IR) spectra were recorded on a JASCO FT/IR 4100 spectrometer. Single crystal X-ray diffraction data were collected at 173K on a Bruker SMART APEX II CCD diffractometer with Mo $\text{K}\alpha$ ($\lambda = 0.71073$) radiation and graphite monochromator. For thin-layer chromatography (TLC) analysis throughout this work, Merck precoated TLC plates (silica gel 60GF254 0.25 mm) were used. The products were purified by neutral column chromatography on silica gel (Kanto Chemical Co., Inc. silica gel 60N, Prod. No. 37560-84; Merck silica gel 60, Prod. No. 1.09385.9929). Visualization was accomplished by UV light (254 nm), anisaldehyde, KMnO_4 , and phosphomolybdic acid. In experiments that required dry solvents such as CH_2Cl_2 , MeCN, CHCl_3 , and THF were distilled in prior to use.

2. Procedure for Preparation of Indolyl(phenyl)iodonium Imides (2a) (Scheme 1; eq. 3).

A mixture of $\text{PhI}(\text{OAc})_2$ (193.3 mg, 0.60 mmol) and Ts_2NH (195.2 mg, 0.60 mmol) in CH_2Cl_2 (5 mL) was stirred at room temperature for 30 min under argon atmosphere. Then, *N*-pivaloyl 2-methyl indol (**1a**) (107.65 mg, 0.50 mmol) was added, and the solution was stirred at room temperature for 2 h. Volatile solvents were removed under reduced pressure. AcOEt (6 mL) was added to the residue, and ether was added dropwise until the solution became cloudy. Then the mixture was sonicated until a white solid appeared and then ether (2 mL) was added to the solution. The precipitated solid was washed with a mixture of AcOEt and hexane (2:1) (15 mL) to give desired product **2a** (322.6 mg, 87 % yield).



4-Methyl-*N*-((2-methyl-1-pivaloyl-1*H*-indol-3-yl)(phenyl)- λ^3 -iodanyl)-*N*-tosylbenzenesulfonamide (2a): ^1H NMR (400 MHz, CDCl_3) δ 1.32 (s, 9H), 2.25 (s, 6H), 2.68 (s, 3H), 6.91 (d, $J = 8.1$ Hz, 4H), 7.21-7.26 (m, 1H), 7.27-7.34 (m, 4H), 7.45 (d, $J = 8.1$ Hz, 4H), 7.43-7.48 (m, 1H), 7.49-7.53 (m, 1H), 7.86-7.91 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 14.4, 21.3 (2C), 27.9 (3C), 44.8, 82.0, 112.2, 115.9, 119.4, 123.5, 124.5, 126.7 (4C), 127.6, 128.4 (4C), 131.4, 131.7 (2C),

133.5 (2C), 135.8, 140.5 (2C), 141.2 (2C), 143.1, 185.2. IR (neat) 1730, 1451, 1263, 1131, 1082, 1035, 814, 746, 669 cm^{-1} . MS (ESI) calcd for $\text{C}_{34}\text{H}_{35}\text{IN}_2\text{NaO}_5\text{S}_2$ $[\text{M}+\text{Na}]^+$ 765.0924, found 765.0908.

Crystal data of 2a: Formula $\text{C}_{34}\text{H}_{35}\text{IN}_2\text{O}_5\text{S}_2$, colorless, crystal dimensions $0.20 \times 0.20 \times 0.10$ mm^3 , Triclinic, space group P -1, $a = 12.2348(9)$ Å, $b = 13.7713(10)$ Å, $c = 21.3593(15)$ Å, $\alpha = 74.8147(9)^\circ$, $\beta = 78.2115(10)^\circ$, $\gamma = 80.1920(9)^\circ$, $V = 3373.8(4)$ Å³, $Z = 4$, $\rho_{\text{calc}} = 1.462$ g cm^{-3} , $F(000) = 1512$, $\mu(\text{MoK}\alpha) = 1.115$ mm^{-1} , $T = 173$ K. 19506 reflections collected, 14722 independent reflections with $I > 2\sigma(I)$ ($2\theta_{\text{max}} = 27.56^\circ$), and 805 parameters were used for the solution of the structure. The non-hydrogen atoms were refined anisotropically. $R_1 = 0.0409$ and $wR_2 = 0.1113$. GOF = 1.044. Crystallographic data (excluding structure factors) for the structure reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC-1532903. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. code + 44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk].




Figure S1. ORTEP drawing of **2a** (dimer structure).





Figure S2. ORTEP drawing of **2a** (monomer unit).

3. Procedure for Iodo-amination of Indolyl(phenyl)iodonium Imides (**2a**) (Scheme 1; eq. 4).


To a solution of 4-methyl-*N*-(phenyl(1-pivaloyl-2-methyl-1*H*-indol-3-yl)- λ^3 -iodanyl)-*N*-tosylbenzenesulfonamide (**2a**) (74.3 mg, 0.10 mmol) in CH_2Cl_2 (1.0 mL) was added 1,3-diiodo-5,5-dimethylhydantoin (22.8 mg, 0.060 mmol). The mixture was stirred at room temperature for 7 h under argon atmosphere. Then, saturated Na_2SO_3 aqueous solution (10 mL) was added to the reaction mixture, and the product was extracted with AcOEt (15 mL \times 3). The combined extracts were washed by water (10 mL) and brine (10 mL), and dried over Na_2SO_4 . The organic phase was concentrated under reduced pressure and the crude product was purified by silica gel column chromatography (eluent: hexane/AcOEt = 5/1), to give the desired product **3a** (61.1 mg, 92 % yield).

Table S1. Screening for Halogen Reagent and Solvent for Halo-amination of **2a**.



Entry	Halogen reagent (equiv.)	Solvent	Yield (%)
1	DBH (0.6)	CH ₂ Cl ₂	54
2	DBH (0.6)	CH ₂ Cl ₂	67
3	DBH (0.6)	THF	7 (81) ^a
4	DBH (0.6)	MeCN	50
5	DBH (0.6)	CHCl ₃	33
6	NBS (1.2)	CH ₂ Cl ₂	70
7	NBA (1.2)	CH ₂ Cl ₂	12
8	NBP (1.2)	CH ₂ Cl ₂	74 (3) ^b
9	NIS (1.2)	CH ₂ Cl ₂	83
10	DIH (0.6)	CH ₂ Cl ₂	85

^a The reaction was carried out without dark conditions. ^b Number in parentheses indicates the yield of *N*-pivaloyl 2-methyl-3-bromo indole.



***N*-((3-Iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-4-methyl-*N*-tosylbenzenesulfonamide (3a):** ¹H NMR (400 MHz, CDCl₃) δ 1.40 (s, 9H), 2.31 (s, 6H), 5.27 (s, 2H), 7.05 (d, *J* = 8.3 Hz, 4H), 7.17-7.31 (m, 4H), 7.63 (d, *J* = 8.3 Hz, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 21.5 (2C), 28.1 (3C), 44.5, 46.8, 72.1, 112.7, 121.7, 122.1, 124.9, 127.8 (4C), 129.1 (4C), 130.2, 130.7, 135.7, 136.8 (2C), 144.5 (2C), 183.6. IR (neat) 1745, 1378, 1166, 996, 549 cm⁻¹. MS (ESI) calcd for C₂₈H₃₀IN₂O₅S₂ [M+H]⁺ 665.0635, found 665.0641.

Crystal data for 3a: Formula C₂₈H₂₉IN₂O₅S₂, colorless, crystal dimensions 0.20 × 0.20 × 0.20 mm³, Monoclinic, space group P 1 21/c 1, *a* = 11.244(3) Å, *b* = 10.311(3) Å, *c* = 24.381(7) Å, α = 90.00°, β = 100.978(4)°, γ = 90.00°, *V* = 2774.9(13) Å³, *Z* = 4, ρ_{calc} = 1.591 g cm⁻³, F(000) = 1344, μ(MoKα) = 1.346 mm⁻¹, *T* = 173 K. 15287 reflections collected, 6332 independent reflections with *I* > 2σ(*I*) (2θ_{max} = 27.69°), and 348 parameters were used for the solution of the structure. The non-hydrogen atoms were refined anisotropically. *R*₁ = 0.0402 and *wR*₂ = 0.1056. GOF = 1.039. Crystallographic data (excluding structure factors) for the structure reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC-1532904. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. code + 44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk].




Figure S3. ORTEP drawing of **3a**.


4. General procedure for Direct Iodo-amination of 2-Methyl Indole Derivatives (1) with $\text{PhI}(\text{OAc})_2$ and DIH (Method A) (Scheme 2; eq. 5, Table 1, and Table 2).

A mixture of $\text{PhI}(\text{OAc})_2$ (38.7 mg, 0.12 mmol), Ts_2NH (39.1 mg, 0.12 mmol) in CH_2Cl_2 (1.0 mL) was stirred at room temperature for 30 min under argon atmosphere. Then, *N*-pivaloyl 2-methyl indole (**1a**) (21.5 mg, 0.10 mmol) was added, and the solution was stirred at room temperature for 2 h. To the solution was added NaHCO_3 (22.1 mg, 0.24 mmol), and the obtained mixture was stirred at room temperature for 10 min, followed by addition of 1,3-diiido-5,5-dimethylhydantoin (22.8 mg, 0.060 mmol). The mixture was stirred at room temperature for 5 h under argon atmosphere. Saturated Na_2SO_3 aqueous solution (10 mL) was added to the reaction mixture, and the product was extracted with AcOEt (15 mL \times 3). The combined extracts were washed by water (10 mL) and brine (10 mL), and dried over Na_2SO_4 . The organic phase was concentrated under reduced pressure and the crude product was purified by silica gel column chromatography (eluent: hexane/ AcOEt = 5/1), to give the desired product **3a** (63.8 mg, 96% yield).

5. General procedure for Direct Iodo-amination of 2-Methyl Indole Derivatives (1) with DIH (Method B) (Scheme 2; eq. 6, Table 1, and Table 2).


To a solution of *N*-pivaloyl 2-methyl indole (**1a**) (21.5 mg, 0.10 mmol) in CH_2Cl_2 (1.0 mL) was added 1,3-diiido-5,5-dimethylhydantoin (60.8 mg, 0.16 mmol), and the mixture was stirred at room temperature for 7 h under argon atmosphere. Saturated Na_2SO_3 aqueous solution (10 mL) was added to the reaction mixture, and the product was extracted with AcOEt (15 mL \times 3). The combined extracts were washed with water (10 mL) and brine (10 mL), and dried over Na_2SO_4 . The organic phase was concentrated under reduced pressure and the crude product was purified by silica gel column chromatography (eluent: hexane/ AcOEt = 5/1), to give the desired product **2a**

(61.1 mg, 92% yield).




***N*-((3-Iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3b):**

^1H NMR (400 MHz, CDCl_3) δ 1.49 (s, 9H), 3.23 (s, 6H), 5.18 (s, 2H), 7.24-7.30 (m, 1H), 7.31-7.37 (m, 1H), 7.39-7.44 (m, 1H), 7.47-7.51 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.2 (3C), 43.7 (2C), 44.2, 45.6, 70.6, 113.4, 122.2, 122.5, 125.0, 130.2, 132.7, 135.6, 184.4. IR (neat) 1692, 1363, 1154, 1004, 529 cm^{-1} . MS (ESI) calcd for $\text{C}_{16}\text{H}_{21}\text{ClIN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 546.9631, found 546.9641.




***N*-((3-Iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(phenylsulfonyl)benzenesulfonamide (3c):**


^1H NMR (400 MHz, CDCl_3) δ 1.42 (s, 9H), 5.30 (s, 2H), 7.17-7.34 (m, 8H), 7.42-7.50 (m, 2H), 7.72-7.79 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.1 (3C), 44.4, 46.9, 72.5, 112.8, 121.9, 122.2, 125.0, 127.9 (4C), 128.5 (4C), 130.1, 130.7, 133.5 (2C), 135.6, 139.6 (2C), 183.7. IR (neat) 1731, 1374, 1167, 999, 546 cm^{-1} . MS (ESI) calcd for $\text{C}_{26}\text{H}_{26}\text{IN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{H}]^+$ 637.0033, found 637.0034.




4-Fluoro-*N*-((4-fluorophenyl)sulfonyl)-*N*-((3-iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)benzenesulfonamide (3d): ^1H NMR (400 MHz, CDCl_3) δ 1.41 (s, 9H), 5.27 (s, 2H), 6.90-7.00 (m, 4H), 7.20-7.37 (m, 4H), 7.72-7.81 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.1 (3C), 44.5, 47.0, 72.3, 112.7, 115.8 (d, $J_{\text{C-F}} = 23.0$ Hz, 4C), 121.8, 122.5, 125.2, 130.0, 130.2, 130.9 (d, $J_{\text{C-F}} = 9.6$ Hz, 4C), 135.5 (d, $J_{\text{C-F}} = 3.8$ Hz, 2C), 135.7, 165.6 (d, $J_{\text{C-F}} = 257.7$ Hz, 2C), 183.7. ^{19}F NMR (369 MHz, CDCl_3) δ -102.9. IR (neat) 1745, 1590, 1492, 1384, 1173, 997, 547 cm^{-1} . MS (ESI) calcd for $\text{C}_{26}\text{H}_{24}\text{F}_2\text{IN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{H}]^+$ 673.0134, found 673.0132.




***N*-((3-Iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-4-methyl-*N*-(methylsulfonyl)benzenesulfonamide (3e):** ^1H NMR (400 MHz, CDCl_3) δ 1.43 (s, 9H), 2.27 (s, 3H), 3.36 (s, 3H), 5.19 (s, 2H), 6.94-7.01 (m, 2H), 7.20-7.26 (m, 1H), 7.29-7.34 (m, 3H), 7.51-7.58 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 21.5, 28.1 (3C), 44.4, 44.6, 46.1, 71.3, 113.0, 121.9, 122.3, 124.9, 128.1 (2C), 129.0 (2C), 130.2, 131.5, 135.5, 135.6, 144.8, 184.0. IR (neat) 1686, 1364, 1163, 962, 558 cm^{-1} . MS (ESI) calcd for $\text{C}_{22}\text{H}_{26}\text{IN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{H}]^+$ 589.0322, found 589.0326.



***N*-(Benzylsulfonyl)-*N*-((3-iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-1-phenylmethanesulfonamide (3f):** ^1H NMR (400 MHz, CDCl_3) δ 1.37 (s, 9H), 4.28 (br, 2H), 4.52 (s, 4H), 7.21-7.42 (m, 13H), 7.46 (d, $J = 7.8$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.0 (3C), 44.0, 47.3, 62.9 (2C), 69.9, 113.0, 122.1, 122.4, 125.1, 126.7 (2C), 128.9 (4C), 129.4 (2C), 130.0, 131.2 (4C), 132.6, 135.5, 183.9. IR (neat) 1691, 1377, 1158, 997, 544 cm^{-1} . MS (ESI) calcd for $\text{C}_{28}\text{H}_{30}\text{IN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{H}]^+$ 665.0635, found 665.0644.




***N*-((3-Iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(propylsulfonyl)propane-1-sulfonamide (3g):** ^1H NMR (400 MHz, CDCl_3) δ 0.96 (t, $J = 7.5$ Hz, 6H), 1.47 (s, 9H), 1.76-1.88 (m, 4H), 3.23-3.30 (m, 4H), 5.17 (s, 2H), 7.24-7.30 (m, 1H), 7.31-7.37 (m, 1H), 7.38-7.44 (m, 1H), 7.46-7.53 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 12.7 (2C), 16.6 (2C), 28.1 (3C), 44.2, 46.2, 58.5 (2C), 70.8, 113.2, 122.2, 122.4, 125.1, 130.1, 132.9, 135.7, 184.2. IR (neat) 2970, 1703, 1370, 1151, 999, 571 cm^{-1} . MS (ESI) calcd for $\text{C}_{20}\text{H}_{30}\text{IN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{H}]^+$ 569.0635, found 569.0641.




***N*-((3-Iodo-6-methyl-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3h):** ^1H NMR (400 MHz, CDCl_3) δ 1.47 (s, 9H), 2.49 (s, 3H), 3.21 (s, 6H), 5.16 (s, 2H), 7.09 (d, $J = 8.2$ Hz, 1H), 7.19 (s, 1H), 7.35 (d, $J = 8.2$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 22.0,


28.2 (3C), 43.7 (2C), 44.2, 45.7, 70.6, 113.3, 121.7, 124.2, 128.1, 131.7, 135.2, 136.0, 184.4. IR (neat) 1706, 1358, 1153, 965, 531 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{23}\text{ClIN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 560.9787, found 560.9794.




***N*-((6-Chloro-3-iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3i):** ^1H NMR (400 MHz, CDCl_3) δ 1.47 (s, 9H), 3.23 (s, 6H), 5.14 (s, 2H), 7.24 (dd, $J = 8.5, 1.8$ Hz, 1H), 7.39 (s, 1H), 7.41 (d, $J = 8.5$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.2 (3C), 43.7 (2C), 44.3, 45.5, 69.8, 113.2, 123.1, 123.2, 128.8, 131.1, 133.3, 135.7, 183.8. IR (neat) 1712, 1358, 1153, 962, 531 cm^{-1} . MS (ESI) calcd for $\text{C}_{16}\text{H}_{20}\text{Cl}_2\text{IN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 580.9241, found 580.9251.




***N*-((6-Fluoro-3-iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3j):** ^1H NMR (400 MHz, CDCl_3) δ 1.48 (s, 9H), 3.23 (s, 6H), 5.15 (s, 2H), 7.04 (td, $J = 9.2, 2.0$ Hz, 1H), 7.13 (dd, $J = 10.0, 2.0$ Hz, 1H), 7.43 (dd, $J = 9.2, 5.6$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.1 (3C), 43.6 (2C), 44.2, 45.6, 70.1, 100.2 (d, $J_{\text{C-F}} = 28.6$ Hz), 111.3 (d, $J_{\text{C-F}} = 24.8$ Hz), 123.3 (d, $J_{\text{C-F}} = 10.5$ Hz), 126.6, 133.1 (d, $J_{\text{C-F}} = 3.8$ Hz), 135.2 (d, $J_{\text{C-F}} = 12.4$ Hz), 161.2 (d, $J_{\text{C-F}} = 246.1$ Hz), 183.8. ^{19}F NMR (369 MHz, CDCl_3) δ -115.4. IR (neat) 1695, 1484, 1363, 1161, 975, 526 cm^{-1} . MS (ESI) calcd for $\text{C}_{16}\text{H}_{20}\text{FClIN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 564.9536, found 564.9538.




***N*-((3,5-Diiodo-6-methoxy-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3k):** ^1H NMR (400 MHz, CDCl_3) δ 1.45 (s, 9H), 3.20 (s, 6H), 3.91 (s, 3H), 5.13 (s, 2H), 6.83 (s, 1H), 7.87 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.2 (3C), 43.7 (2C), 44.6, 45.7, 56.7, 68.8, 80.9, 95.5, 126.1, 131.6, 132.4, 136.3, 155.9, 183.9. IR (neat) 1702, 1360, 1151, 1041, 976, 529 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{22}\text{ClI}_2\text{N}_2\text{O}_6\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 702.8703, found 702.8712.




N-((3-Iodo-1-pivaloyl-6-(trifluoromethyl)-1H-indol-2-yl)methyl)-N-(methylsulfonyl)methanesulfonamide (3l): ^1H NMR (400 MHz, CDCl_3) δ 1.48 (s, 9H), 3.25 (s, 6H), 5.18 (s, 2H), 7.51 (d, $J = 8.4$ Hz, 1H), 7.60 (d, $J = 8.4$ Hz, 1H), 7.68 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.2 (3C), 43.6 (2C), 44.4, 45.3, 69.2, 110.6 (q, $J_{\text{C-F}} = 3.8$ Hz), 119.1 (q, $J_{\text{C-F}} = 3.8$ Hz), 122.8, 124.3 (q, $J_{\text{C-F}} = 273.0$ Hz), 127.1 (q, $J_{\text{C-F}} = 32.6$ Hz), 132.5, 134.6, 135.4, 183.7. ^{19}F NMR (369 MHz, CDCl_3) δ -61.2. IR (neat) 1699, 1329, 1149, 1114, 974, 531 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{20}\text{ClF}_3\text{IN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 614.9504, found 614.9511.



Methyl 3-iodo-2-((N-(methylsulfonyl)methylsulfonamido)methyl)-1-pivaloyl-1H-indole-6-carboxylate (3m): ^1H NMR (400 MHz, CDCl_3) δ 1.50 (s, 9H), 3.26 (s, 6H), 3.96 (s, 3H), 5.18 (s, 2H), 7.73 (dd, $J = 8.4, 0.4$ Hz, 1H), 7.94 (dd, $J = 8.4, 1.4$ Hz, 1H), 8.16-8.21 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.3 (3C), 43.6 (2C), 44.3, 45.3, 52.4, 69.5, 115.3, 121.9, 123.3, 126.7, 133.6, 135.0, 135.8, 167.0, 184.0. IR (neat) 1719, 1343, 1236, 1155, 979, 528 cm^{-1} . MS (ESI) calcd for $\text{C}_{18}\text{H}_{23}\text{ClIN}_2\text{O}_7\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 604.9685, found 604.9692.




N-((3-Iodo-6-nitro-1-pivaloyl-1H-indol-2-yl)methyl)-N-(methylsulfonyl)methanesulfonamide (3n): ^1H NMR (400 MHz, CDCl_3) δ 1.53 (s, 9H), 3.22 (s, 6H), 5.11 (s, 2H), 7.58 (d, $J = 8.9$ Hz, 1H), 8.08 (d, $J = 1.8$ Hz, 1H), 8.14 (dd, $J = 8.9, 1.8$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 27.2 (3C), 39.4, 43.8 (2C), 44.3, 62.4, 105.3, 117.3, 123.1, 131.1, 133.7, 136.8, 145.4, 176.3. IR (neat) 1793, 1514, 1335, 1159, 1011, 523 cm^{-1} . MS (APPI) calcd for $\text{C}_{14}\text{H}_{14}\text{IN}_2\text{O}_3$ $[\text{M}-\text{NMs}_2]^+$ 385.0044, found 385.0045.




N-((3-Iodo-5-methyl-1-pivaloyl-1H-indol-2-yl)methyl)-N-(methylsulfonyl)methanesulfonamide (3o): ^1H NMR (400 MHz, CDCl_3) δ 1.48 (s, 9H), 2.47 (s, 3H), 3.22 (s, 6H), 5.17 (s, 2H), 7.15


(dd, $J = 8.5, 1.4$ Hz, 1H), 7.26 (m, 1H), 7.32 (d, $J = 8.5$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 21.1, 28.2 (3C), 43.7 (2C), 43.9, 45.6, 70.6, 113.3, 121.8, 126.6, 130.4, 132.3, 132.7, 133.8, 184.2. IR (neat) 1728, 1362, 1157, 993, 521 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{23}\text{ClIN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 560.9787, found 560.9801.




***N*-((5-Bromo-3-iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3p):** ^1H NMR (400 MHz, CDCl_3) δ 1.45 (s, 9H), 3.24 (s, 6H), 5.15 (s, 2H), 7.27 (d, $J = 8.9$ Hz, 1H), 7.42 (dd, $J = 8.9, 2.0$ Hz, 1H), 7.64 (d, $J = 2.0$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.2 (3C), 43.7 (2C), 44.3, 45.4, 68.7, 114.7, 115.9, 124.8, 127.9, 132.0, 133.9, 134.3, 183.9. IR (neat) 1729, 1362, 1159, 992, 525 cm^{-1} . MS (ESI) calcd for $\text{C}_{16}\text{H}_{20}\text{BrClIN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 624.8736, found 624.8746.




***N*-((5-Chloro-3-iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3q):** ^1H NMR (400 MHz, CDCl_3) δ 1.46 (s, 9H), 3.24 (s, 6H), 5.15 (s, 2H), 7.28 (dd, $J = 9.2, 2.0$ Hz, 1H), 7.33 (dd, $J = 9.2, 0.5$ Hz, 1H), 7.48 (dd, $J = 2.0, 0.5$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.2 (3C), 43.7 (2C), 44.3, 45.4, 68.9, 114.4, 121.7, 125.3, 128.5, 131.5, 134.0, 134.1, 183.9. IR (neat) 1730, 1362, 1159, 992, 522 cm^{-1} . MS (ESI) calcd for $\text{C}_{16}\text{H}_{20}\text{Cl}_2\text{IN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 580.9241, found 580.9254.




***N*-((5-Fluoro-3-iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3r):** ^1H NMR (400 MHz, CDCl_3) δ 1.47 (s, 9H), 3.24 (s, 6H), 5.15 (s, 2H), 7.07 (d, $J = 9.1, 2.5$ Hz, 1H), 7.17 (dd, $J = 8.7, 2.5$ Hz, 1H), 7.35 (dd, $J = 9.1, 4.1$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.2 (3C), 43.7 (2C), 44.2, 45.5, 69.4, 107.5 (d, $J_{\text{C-F}} = 24.9$ Hz), 113.4 (d, $J_{\text{C-F}} = 25.9$ Hz), 114.5 (d, $J_{\text{C-F}} = 8.6$ Hz), 131.4 (d, $J_{\text{C-F}} = 10.5$ Hz), 132.0, 134.4, 159.1 (d, $J_{\text{C-F}} = 241.4$ Hz), 184.0. ^{19}F NMR (369 MHz, CDCl_3) δ -120.1. IR (neat) 1698, 1366, 1160, 979, 510 cm^{-1} . MS (ESI) calcd for $\text{C}_{16}\text{H}_{20}\text{ClFIN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 564.9536, found 564.9548.




***N*-((3,6-Diiodo-5-methoxy-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3s):** ^1H NMR (400 MHz, CDCl_3) δ 1.46 (s, 9H), 3.23 (s, 6H), 3.97 (s, 3H), 5.14 (s, 2H), 6.83 (s, 1H), 7.84 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.3 (3C), 43.7 (2C), 44.1, 45.5, 56.7, 70.0, 83.8, 102.2, 124.2, 131.1, 131.4, 133.5, 154.1, 183.6. IR (neat) 1694, 1365, 1161, 978, 531 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{22}\text{ClI}_2\text{N}_2\text{O}_6\text{S}_2$ [$\text{M}+\text{Cl}$] $^-$ 702.8703, found 702.8722.



***N*-((5-Cyano-3-iodo-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3t):** ^1H NMR (400 MHz, CDCl_3) δ 1.46 (s, 9H), 3.26 (s, 6H), 5.15 (s, 2H), 7.44 (dd, $J = 8.7, 0.7$ Hz, 1H), 7.57 (dd, $J = 8.7, 1.6$ Hz, 1H), 7.86 (dd, $J = 1.6, 0.7$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.1 (3C), 43.6 (2C), 44.7, 45.2, 68.9, 106.1, 114.0, 119.1, 127.56, 127.59, 130.3, 135.1, 137.3, 183.7. IR (neat) 2230, 1709, 1347, 1156, 1005, 538 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{20}\text{ClIN}_3\text{O}_5\text{S}_2$ [$\text{M}+\text{Cl}$] $^-$ 571.9583, found 571.9599.




***N*-((3-Iodo-5-nitro-1-pivaloyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3u):** ^1H NMR (400 MHz, CDCl_3) δ 1.47 (s, 9H), 3.27 (s, 6H), 5.15 (s, 2H), 7.45 (d, $J = 9.4$ Hz, 1H), 8.23 (dd, $J = 9.4, 2.2$ Hz, 1H), 8.46 (d, $J = 2.2$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.1 (3C), 43.6 (2C), 44.8, 45.2, 69.9, 113.3, 119.1, 120.0, 130.2, 136.0, 138.4, 143.5, 183.6. IR (neat) 1714, 1520, 1361, 1154, 974, 532 cm^{-1} . MS (ESI) calcd for $\text{C}_{16}\text{H}_{20}\text{ClIN}_3\text{O}_7\text{S}_2$ [$\text{M}+\text{Cl}$] $^-$ 591.9481, found 591.9485.




Methyl 3-iodo-2-((*N*-(methylsulfonyl)methylsulfonyl)methyl)-1-pivaloyl-1*H*-indole-5-carboxylate (3v): ^1H NMR (400 MHz, CDCl_3) δ 1.51 (s, 9H), 3.19 (s, 6H), 3.94 (s, 3H), 5.10 (s, 2H), 7.49 (d, $J = 8.5$ Hz, 1H), 7.87 (d, $J = 1.4$ Hz, 1H), 7.92 (dd, $J = 8.5, 1.4$ Hz, 1H). ^{13}C NMR


(100 MHz, CDCl₃) δ 27.2 (3C), 39.3, 43.9 (2C), 44.5, 52.3, 63.0, 110.8, 122.3, 123.1, 127.0, 130.2, 134.5, 134.8, 166.9, 176.5. IR (neat) 1781, 1716, 1351, 1248, 1159, 1072, 966, 521 cm⁻¹. MS (APCI) calcd for C₁₈H₂₃IN₂O₇S₂ [M]⁺ 569.9986, found 569.9991.




N-((3-Iodo-4-methyl-1-pivaloyl-1H-indol-2-yl)methyl)-N-(methylsulfonyl)methanesulfonamide (3w): ¹H NMR (400 MHz, CDCl₃) δ 1.40 (s, 9H), 2.92 (s, 3H), 3.23 (s, 6H), 5.18 (s, 2H), 6.93-6.99 (m, 1H), 7.11-7.18 (m, 1H), 7.22-7.28 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 20.3, 28.3 (3C), 43.6 (2C), 44.9, 46.3, 66.8, 111.3, 124.0, 124.4, 125.8, 131.3, 132.0, 136.1, 184.7. IR (neat) 1732, 1366, 1158, 961, 526 cm⁻¹. MS (ESI) calcd for C₁₇H₂₃ClIN₂O₅S₂ [M+Cl]⁻ 560.9787, found 560.9792.




N-((5,6-Dichloro-3-iodo-1-pivaloyl-1H-indol-2-yl)methyl)-N-(methylsulfonyl)methanesulfonamide (3x): ¹H NMR (400 MHz, CDCl₃) δ 1.46 (s, 9H), 3.24 (s, 6H), 5.12 (s, 2H), 7.52 (s, 1H), 7.58 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 28.2 (3C), 43.6 (2C), 44.3, 45.3, 68.3, 114.8, 123.1, 127.1, 129.2, 130.0, 134.0, 134.7, 183.4. IR (neat) 1712, 1353, 1156, 971, 530 cm⁻¹. MS (ESI) calcd for C₁₆H₁₉Cl₃IN₂O₅S₂ [M+Cl]⁻ 614.8851, found 614.8857.




N-((3,4-Diiodo-5,7-dimethyl-1-pivaloyl-1H-indol-2-yl)methyl)-N-(methylsulfonyl)methanesulfonamide (3y): ¹H NMR (400 MHz, CDCl₃) δ 1.09 (s, 9H), 2.56 (s, 3H), 2.60 (s, 3H), 3.28 (s, 6H), 5.08 (s, 2H), 7.24 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 26.0, 27.7 (3C), 30.1, 43.4 (2C), 45.6, 47.2, 71.6, 106.8, 119.8, 126.8, 130.6, 131.7, 135.1, 136.4, 186.6. IR (neat) 1712, 1372, 1157, 1030, 527 cm⁻¹. MS (ESI) calcd for C₁₈H₂₄ClI₂N₂O₅S₂ [M+Cl]⁻ 700.8910, found 700.8916.




***N*-((1-Iodo-3-pivaloyl-3*H*-benzo[*e*]indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3z-H):** ^1H NMR (400 MHz, CDCl_3) δ 1.39 (s, 9H), 3.19 (s, 6H), 5.28 (s, 2H), 7.42 (d, $J = 9.1$ Hz, 1H), 7.49-7.56 (m, 1H), 7.65-7.71 (m, 2H), 7.92 (d, $J = 8.2$ Hz, 1H), 7.61 (d, $J = 8.5$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.2 (3C), 43.8 (2C), 45.5, 46.5, 66.7, 112.9, 120.2, 121.4, 124.8, 125.9, 126.2, 127.9, 128.8, 129.2, 130.2, 133.3, 184.6. IR (neat) 1731, 1361, 1154, 960, 529 cm^{-1} . MS (ESI) calcd for $\text{C}_{20}\text{H}_{23}\text{ClIN}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 596.9787, found 596.9794.



***N*-((1,5-Diiodo-3-pivaloyl-3*H*-benzo[*e*]indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3z-I):** ^1H NMR (400 MHz, CDCl_3) δ 1.40 (s, 9H), 3.20 (s, 6H), 5.26 (s, 2H), 7.57-7.64 (m, 1H), 7.69-7.75 (m, 1H), 8.06 (s, 1H), 8.21-8.26 (m, 1H), 9.56-9.61 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 28.2 (3C), 43.7 (2C), 45.6, 46.3, 66.4, 95.7, 120.8, 121.7, 124.3, 126.3, 126.9, 127.9, 129.9, 130.2, 133.4, 133.7, 184.0. IR (neat) 1729, 1367, 1153, 1002, 528 cm^{-1} . MS (ESI) calcd for $\text{C}_{20}\text{H}_{22}\text{ClI}_2\text{N}_2\text{O}_5\text{S}_2$ $[\text{M}+\text{Cl}]^-$ 722.8754, found 722.8764.




***N*-((1-Benzoyl-3-iodo-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3aa):** ^1H NMR (400 MHz, CDCl_3) δ 3.28 (s, 6H), 5.54 (s, 2H), 6.46 (d, $J = 8.7$ Hz, 1H), 7.03-7.09 (m, 1H), 7.20-7.26 (m, 1H), 7.47 (d, $J = 8.0$ Hz, 1H), 7.50-7.56 (m, 2H), 7.76-7.73 (m, 1H), 7.80-7.86 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 42.7 (2C), 44.8, 75.2, 114.1, 122.1, 123.3, 125.3, 129.0 (2C), 130.4 (2C), 130.5, 133.8, 134.1, 134.9, 136.7, 169.4. IR (neat) 1685, 1375, 1158, 977, 745 cm^{-1} . MS (ESI) calcd for $\text{C}_{18}\text{H}_{17}\text{IN}_2\text{NaO}_5\text{S}_2$ $[\text{M}+\text{Na}]^+$ 554.9516, found 554.9519.




***N*-((3-Iodo-1-tosyl-1*H*-indol-2-yl)methyl)-*N*-(methylsulfonyl)methanesulfonamide (3ab):** ^1H

NMR (400 MHz, CDCl₃) δ 2.34 (s, 3H), 3.49 (s, 6H), 5.46 (s, 2H), 7.16-7.23 (m, 2H), 7.28-7.35 (m, 1H), 7.35-7.43 (m, 2H), 7.61-7.68 (m, 2H), 8.03-8.09 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 21.6, 42.8 (2C), 45.5, 80.8, 115.3, 122.5, 124.7, 126.5 (2C), 126.9, 130.1 (2C), 131.5, 132.8, 134.8, 136.7, 145.5. IR (neat) 1372, 1359, 1174, 1154, 996, 569 cm⁻¹. MS (ESI) calcd for C₁₈H₁₉IN₂NaO₆S₃ [M+Na]⁺ 604.9342, found 604.9348.


6. Derivatization of 2-Aminomethyl-3-iodo indole Derivatives (**3b**) (Scheme 5).



To a solution of **3b** (2.03 g, 3.50 mmol) in toluene (44 mL) was added Red-Al[®] (60 wt. % toluene solution; 2.85 mL, 8.75 mmol) dropwise at -20 °C, and the reaction mixture was stirred at 0 °C for 1 h under argon atmosphere. Saturated NH₄Cl aqueous solution (50 mL) was added to the mixture at 0 °C, and the product was extracted with AcOEt (50 mL × 3). The organic phase was washed with brine (50 mL), and dried over Na₂SO₄. The solvent was removed under reduced pressure. The crude mixture was purified by column chromatography (eluent: hexane/AcOEt=2/1) to give the desired product **5** (455.2 mg, 37% yield).




N-((3-Iodo-1H-indol-2-yl)methyl)methanesulfonamide (5): ¹H NMR (400 MHz, MeCN-*d*₃) δ 2.89 (s, 3H), 4.41 (s, 2H), 5.72 (brs, 1H), 7.11-7.17 (m, 1H), 7.18-7.25 (m, 1H), 7.29-7.35 (m, 1H), 7.38-7.43 (m, 1H), 9.78 (brs, 1H). ¹³C NMR (100 MHz, MeCN-*d*₃) δ 40.4, 41.5, 59.0, 112.7, 121.2, 121.5, 124.1, 131.1, 136.6, 137.4. IR (neat) 3381, 3303, 1310, 1148, 1068, 589 cm⁻¹. MS (ESI) calcd for C₁₀H₁₂IN₂O₂S [M+H]⁺ 350.9659, found 350.9651.




To a solution of **5** (70.0 mg, 0.20 mmol) in DMF (0.8 mL) and THF (0.8 mL) was added Boc₂O (183.0 μL, 0.80 mmol) and DMAP (2.4 mg, 0.020 mmol), and the mixture was stirred at room


temperature for 16 h. The solvent was removed under reduced pressure and the crude mixture was purified by column chromatography (eluent: hexane/AcOEt=5/1) to give the desired product **6** (109.0 mg, >99% yield).



tert-Butyl 2-((N-(tert-butoxycarbonyl)methylsulfonamido)methyl)-3-iodo-1H-indole-1-carboxylate (6): ^1H NMR (400 MHz, CDCl_3) δ 1.51 (s, 9H), 1.70 (s, 9H), 3.04 (s, 3H), 5.45 (s, 2H), 7.27-7.33 (m, 1H), 7.33-7.39 (m, 1H), 7.41-7.47 (m, 1H), 7.93-7.98 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 27.9 (3C), 28.1 (3C), 42.3, 43.9, 74.0, 84.6, 85.3, 115.4, 121.8, 123.4, 125.7, 130.8, 135.2, 135.7, 149.4, 151.6. IR (neat) 1729, 1353, 1237, 1143, 543 cm^{-1} . MS (ESI) calcd for $\text{C}_{20}\text{H}_{28}\text{IN}_2\text{O}_6\text{S}$ $[\text{M}+\text{H}]^+$ 551.0707, found 551.0707.




To a solution of **6** (110.1 mg, 0.20 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (11.6 mg, 0.010 mmol) in toluene (1 mL) was added tributylvinyltin (70.2 μL , 0.24 mmol), and the reaction mixture was stirred at 80 $^\circ\text{C}$ for 4 h under argon atmosphere. Water (10 mL) was added to the mixture and the organic phase was extracted with AcOEt (10 mL \times 3). The organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The crude mixture was purified by column chromatography (10% w/w anhydrous K_2CO_3 -silica gel, eluent: hexane/AcOEt=7/1) to give the desired product **7** (81.5 mg, 90% yield).




tert-Butyl 2-((N-(tert-butoxycarbonyl)methylsulfonamido)methyl)-3-vinyl-1H-indole-1-carboxylate (7): ^1H NMR (400 MHz, CDCl_3) δ 1.51 (s, 9H), 1.70 (s, 9H), 2.95 (s, 3H), 5.43 (s, 2H), 5.51 (dd, J = 11.6, 1.4 Hz, 1H), 5.77 (dd, J = 18.0, 1.4 Hz, 1H), 6.92 (dd, J = 18.0, 11.6 Hz, 1H), 7.23-7.29 (m, 1H), 7.29-7.35 (m, 1H), 7.80 (d, J = 7.6 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 27.8 (3C), 28.2 (3C), 41.3, 41.9, 84.5, 84.7, 115.3, 118.0, 120.1, 120.6, 123.0, 124.8, 127.2, 127.9, 132.2, 136.0, 150.2, 151.6. IR (neat) 1727, 1453, 1240, 1140 cm^{-1} .

MS (ESI) calcd for C₂₂H₃₁N₂O₆S [M+H]⁺ 451.1897, found 451.1894.



To a solution of **7** (45.1 mg, 0.10 mmol) in CH₂Cl₂ (2 mL) was added 4-phenyl-1,2,4-triazoline-3,5-dione (19.3 mg, 0.11 mmol) at -78 °C, the mixture was stirred at -78 °C for 1.5 h under argon atmosphere. The solvent was removed under reduced pressure and the crude mixture was purified by column chromatography (eluent: hexane/AcOEt=1/1) to give the desired product **8** (61.9 mg, >99% yield).



tert-Butyl 11a-((N-(tert-butoxycarbonyl)methylsulfonamido)methyl)-1,3-dioxo-2-phenyl-2,3,5,11a-tetrahydro-1H,11H-[1,2,4]triazolo[1',2':1,2]pyridazino[3,4-b]indole-11-carboxylate (8): ¹H NMR (400 MHz, MeCN-*d*₃ (60 °C)) δ 1.37 (s, 9H), 1.59 (s, 9H), 2.89 (brs, 3H), 4.57 (dd, *J* = 17.2, 2.8 Hz, 1H), 4.70 (dd, *J* = 17.2, 7.2 Hz, 1H), 4.80 (d, *J* = 16.0 Hz, 1H), 5.26 (d, *J* = 16.0 Hz, 1H), 6.42 (dd, *J* = 6.8, 2.8 Hz, 1H), 7.04-7.10 (m, 1H), 7.28-7.35 (m, 1H), 7.36-7.43 (m, 3H), 7.43-7.53 (m, 3H), 7.91 (d, *J* = 8.8 Hz, 1H). ¹³C NMR (100 MHz, MeCN-*d*₃ (60 °C)) δ 28.1 (3C), 28.7 (3C), 43.3, 45.6, 46.5, 83.2, 84.2, 86.4, 115.4, 116.5, 121.7, 124.4, 125.6, 127.9 (2C), 129.5, 130.1 (2C), 131.9, 133.3, 139.6, 145.9, 149.4, 152.1, 152.9, 155.2. IR (neat) 1716, 1407, 1356, 1154, 753 cm⁻¹. MS (ESI) calcd for C₃₀H₃₅N₅O₈S [M+H]⁺ 626.2279, found 626.2268.

Crystal data for 8: Formula C₃₀H₃₅N₅O₈S, colorless, crystal dimensions 0.20 × 0.20 × 0.10 mm³, Monoclinic, space group P 1 21/c 1', *a* = 15.0230(15) Å, *b* = 12.3995(12) Å, *c* = 17.7457(17) Å, α = 90.00°, β = 112.6609(12)°, γ = 90.00°, *V* = 3050.4(5) Å³, *Z* = 4, ρ_{calc} = 1.362 g cm⁻³, F(000) = 1320, μ(MoKα) = 0.165 mm⁻¹, *T* = 173 K. 17156 reflections collected, 6907 independent reflections with *I* > 2σ(*I*) (2θ_{max} = 27.48°), and 404 parameters were used for the solution of the structure. The non-hydrogen atoms were refined anisotropically. *R*₁ = 0.0449 and *wR*₂ = 0.1090. GOF = 0.993. Crystallographic data (excluding structure factors) for the structure reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC-1589706. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. code + 44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk].






Figure S4. ORTEP drawing of **8**.




A solution of **6** (79.5 mg, 0.144 mmol), Pd(PPh₃)₄ (16.6 mg, 0.0144 mmol), 2-(Methoxycarbonyl)phenylboronic Acid (64.8 mg, 0.360 mmol), K₃PO₄ (115.0 mg, 0.540 mmol) in DMF (1.2 mL) and MeOH (300 μL) was stirred at 60 °C for 3 h under argon atmosphere. Saturated NH₄Cl aqueous solution (10 mL) was added to the mixture at 0 °C, and the product was extracted with AcOEt (10 mL × 3). The organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The crude mixture was purified by column chromatography (eluent: hexane/CHCl₃/AcOEt=10/10/1) to give the desired product **9** (62.9 mg, 78% yield).




tert-Butyl

2-((*N*-(*tert*-butoxycarbonyl)methylsulfonamido)methyl)-3-(2-(methoxycarbonyl)phenyl)-1*H*-indole-1-carboxylate (9**):** ^1H NMR (400 MHz, CDCl_3) δ 1.40 (s, 9H), 1.73 (s, 9H), 2.83 (s, 3H), 3.59 (s, 3H), 5.20 (d, $J = 16.4$ Hz, 1H), 5.38 (d, $J = 16.4$ Hz, 1H), 7.05-7.11 (m, 1H), 7.11-7.18 (m, 1H), 7.26-7.32 (m, 1H), 7.41-7.46 (m, 1H), 7.46-7.52 (m, 1H), 7.58-7.65 (m, 1H), 7.98-8.08 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 27.7 (3C), 28.2 (3C), 41.7, 41.8, 51.9, 84.1, 84.4, 115.2, 119.3, 122.8, 123.8, 124.5, 127.9, 129.9, 130.5, 130.9, 131.4, 132.0, 132.7, 133.6, 135.1, 150.4, 151.5, 167.0. IR (neat) 1731, 1362, 1347, 1146, 1091, 751 cm^{-1} . MS (ESI) calcd for $\text{C}_{28}\text{H}_{35}\text{N}_2\text{O}_8\text{S}$ $[\text{M}+\text{H}]^+$ 559.2109, found 559.2110.




A solution of **9** (158.7 mg, 0.284 mmol) and NaOMe (153.4 mg, 2.84 mmol) in MeOH (2.8 mL) was refluxed for 16 h under argon atmosphere. Saturated NH_4Cl aqueous solution (10 mL) was added to the mixture, and the product was extracted with AcOEt (10 mL \times 3). The organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The crude mixture was purified by column chromatography (eluent: hexane/ AcOEt=2/1) to give the desired product **10** (66.2 mg, 69% yield).




Methyl 2-(2-(methylsulfonamidomethyl)-1*H*-indol-3-yl)benzoate (10**):** ^1H NMR (400 MHz, CDCl_3) δ 2.90 (s, 3H), 3.60 (s, 3H), 4.17 (dd, $J = 15.4, 4.4$ Hz, 1H), 4.31 (dd, $J = 15.4, 8.2$ Hz, 1H), 5.39 (dd, $J = 8.2, 4.4$ Hz, 1H), 7.01-7.08 (m, 1H), 7.14-7.21 (m, 1H), 7.21-7.27 (m, 1H), 7.34 (d, $J = 8.4$ Hz, 1H), 7.36-7.41 (m, 1H), 7.41-7.48 (m, 1H), 7.52-7.59 (m, 1H), 7.86-7.92 (m, 1H), 8.99 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 39.2, 40.6, 52.4, 111.2, 114.4, 119.0, 120.0, 122.6, 127.2,


128.0, 129.8, 131.0, 131.5, 132.0, 132.9, 134.1, 135.4, 168.9. IR (neat) 3387, 3285, 1707, 1430, 1325, 1152, 1093, 743 cm^{-1} . MS (ESI) calcd for $\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$ 359.1060, found 359.1057.



To a solution of **10** (65.2 mg, 0.182 mmol) in THF (1.8 mL) was added LiAlH_4 (13.8 mg, 0.364 mmol) at 0 °C, and the mixture was stirred at room temperature for 1 h under argon atmosphere. Saturated Na_2SO_4 aqueous solution (10 mL) was added to the mixture at 0 °C, and Na_2SO_4 (5 g) was added to the solution. The resulting mixture was filtered with Celite, and the filtrate was extracted with AcOEt (10 mL \times 3). The organic phase was dried over Na_2SO_4 , and concentrated under reduced pressure. The crude mixture was purified by column chromatography (eluent: hexane/AcOEt=1/1 to 1/2) to give the desired product **S1** (59.8 g, >99% yield).




N-((3-(2-(Hydroxymethyl)phenyl)-1H-indol-2-yl)methyl)methanesulfonamide (S1): ^1H NMR (400 MHz, CDCl_3) δ 2.00 (brs, 1H), 2.90 (s, 3H), 4.10 (dd, $J = 15.4, 4.0$ Hz, 1H), 4.30 (dd, $J = 15.4, 8.4$ Hz, 1H), 4.35 (d, $J = 12.0$ Hz, 1H), 4.48 (d, $J = 12.0$ Hz, 1H), 5.89 (dd, $J = 8.4, 4.0$ Hz, 1H), 7.03-7.11 (m, 1H), 7.16-7.27 (m, 2H), 7.29-7.35 (m, 1H), 7.37-7.48 (m, 3H), 7.49-7.55 (m, 1H), 8.93 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 38.5, 40.5, 63.3, 111.3, 114.5, 119.4, 120.1, 122.8, 128.09, 128.15 (2C), 129.6, 131.6, 132.1, 133.4, 135.4, 139.9. IR (neat) 3383, 1455, 1306, 1142, 1057, 744 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}_3\text{S}$ $[\text{M}+\text{H}]^+$ 331.1111, found 331.1111.




To a solution of **S1** (58.2 mg, 0.176 mmol) in CH_2Cl_2 (1.8 mL) was added PPh_3 (72.1 mg, 0.275


mmol) and CBr_4 (91.2 mg, 0.275 mmol) at 0 °C, and the mixture was stirred room temperature for 1 h under argon atmosphere. The crude mixture was purified by column chromatography (eluent: hexane/AcOEt=2/3) to give the desired product **11** (49.5 mg, 72% yield).



N-((3-(2-(Bromomethyl)phenyl)-1H-indol-2-yl)methyl)methanesulfonamide (11): ^1H NMR (400 MHz, CDCl_3) δ 2.97 (s, 3H), 4.27 (dd, $J = 15.6, 5.2$ Hz, 1H), 4.361 (d, $J = 9.8$ Hz, 1H), 4.362 (dd, $J = 15.6, 7.8$ Hz, 1H), 4.42 (d, $J = 9.8$ Hz, 1H), 4.94 (dd, $J = 7.8, 5.2$ Hz, 1H), 7.04-7.11 (m, 1H), 7.13-7.19 (m, 1H), 7.20-7.28 (m, 2H), 7.35-7.47 (m, 3H), 7.56-7.61 (m 1H), 9.03 (s, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 33.3, 38.8, 40.9, 111.4, 113.8, 119.1, 120.3, 123.0, 127.9, 128.6, 128.9, 130.7, 131.3, 132.4, 133.6, 135.6, 137.9. IR (neat) 3377, 3316, 1405, 1306, 1156, 1054, 749 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{18}\text{BrN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ 393.0267, found 393.0264.



To a solution of **11** (49.5 mg, 0.126 mmol) in DMF (1.3 mL) was added K_2CO_3 (87.0 mg, 0.630 mmol), and the mixture was stirred room temperature for 3 h under argon atmosphere. Saturated NH_4Cl aqueous solution (10 mL) was added to the mixture, and the product was extracted with AcOEt (10 mL \times 3). The organic phase was dried over Na_2SO_4 , and concentrated under reduced pressure. The crude mixture was purified by column chromatography (eluent: hexane/AcOEt=2/3) to give the desired product **12** (36.2 mg, 92% yield).



6-(Methylsulfonyl)-5,6,7,8-tetrahydrobenzo[5,6]azepino[3,4-*b*]indole (12): ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 2.59 (s, 3H), 4.33 (s, 2H), 4.76 (s, 2H), 7.07-7.14 (m, 1H), 7.15-7.21 (m, 1H), 7.21-7.27 (m, 1H), 7.38-7.45 (m, 2H), 7.45-7.52 (m 1H), 7.85 (d, $J = 8.0$ Hz, 1H), 7.87-7.92 (m, 1H), 11.59 (s, 1H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 36.9, 45.9, 50.6, 111.2, 111.6, 118.8,

120.0, 122.0, 125.1, 125.9, 127.2, 128.5, 130.0, 133.2, 134.3, 134.9, 136.1. IR (neat) 3375, 2920, 1728, 1456, 1320, 1139, 1071 752 cm^{-1} . MS (ESI) calcd for $\text{C}_{17}\text{H}_{17}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$ 313.1005, found 313.1007.

